BE639532A - - Google Patents
Info
- Publication number
- BE639532A BE639532A BE639532DA BE639532A BE 639532 A BE639532 A BE 639532A BE 639532D A BE639532D A BE 639532DA BE 639532 A BE639532 A BE 639532A
- Authority
- BE
- Belgium
- Prior art keywords
- oil
- association
- formula
- water
- desc
- Prior art date
Links
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 235000000112 undernutrition Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 210000002969 Egg Yolk Anatomy 0.000 claims 1
- 241000536399 Tina Species 0.000 claims 1
- 235000013345 egg yolk Nutrition 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 101700075458 rol-3 Proteins 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 description 15
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
- 229960004203 Carnitine Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229960001518 levocarnitine Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 241000144080 Alestes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 102100008701 TTN Human genes 0.000 description 1
- 101710023457 TTN Proteins 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
<Desc/Clms Page number 1>
EMI1.1
A$.3\.:C!A T IvN D'; LA C ".1'1 l'1'!NE A DES ' Etalh:IGI4 lipidiques.
EMI1.2
La prii5ente invention ne rapporte à une ..aoo.A,.tior:t'; do la 41- ou 1-carnitint, ci-npr'.-a dnocoet carrliU.t1., . -'' "',,,' des mu18iou l1p1d&quen destinées la perfusion ou à "# ' , l' t\dmini fd.l'ta t10n orale ou nt.fr"lt) cette as4unistion ayant cocife but d'obtenir une meilleure utilil11\UÓn tissulaire des lipides danc les enti de dedqui,1ibre inétabalique et . , ttotamment dans* 1 ':1 Lt uyndr';)1:I\<J8 de dénutrition 'êt101olh 4i.. '. verne, pré- et poat'-operatoireu, poat-infectîeux, pe8t tr*iU- MftHqmc, leu hypotropnles, le ebn de nenouciencit ou de leu cachexies( les brûluren, Lut ttuisionte lipi'tiquea !.ont actuellement adIl1niatr... dn8 des citr, de dénutrition tela que ceux cités oi-dt*8U dans le but dtutuurer z 1'organisée un apport e*lorique suffi- eant aouj un volume raiuocnnble.
<Desc/Clms Page number 2>
EMI2.1
On oomprwud, copondunt, tt ceci alest vérifié <xp4ri- rsrr:tslHr.ont, qui l'introduction da quantités importante de Kraiaaett Anna l' or gnn Lutta n'ttcoompt.gno de -/;# production de corps uutoniquea et an conséquence par un 6tuk plus ou Gloinu tiot d'fidoctoe.
En vue dn fraai7 i tu Ilutilititition des graîlla#4 ainsi hdministréen certains nutoura ont ddj& pràcaniué l'adtBiHitt" traction simultanée d'un certain nombre de substance telle que la mt.hi.onitie, la riboflHvino l'acide ascorbique) l'ttoidt pecrrtatlrnique 1.'uride iiicatimîquu# le gaucarra, la. thiamine$ la pyridoxiuft le co-snxynie A# l'héparine et d'autres substances héparoïdes.
Il est connu que la cnrnitine possède des propriété bio-
EMI2.2
eliimiquen permettant de ftivoriser l'oxydation des acides 8;r <(t par la cellule vivante. Cou constixtationa expérimentale ofCec-,- tuées in vitro ont été confirmées in vivo et notamment chez le
EMI2.3
lupin à ,jeun où l'on conatate que la ournitine atabilise le pH et la réserve ulcalitie du Dt,ng$ ce qui indique que la /substance , minci ec.ployée provoque une meilleure utilisation des lipides par l'orgun3.rzue. ¯,; L'objet de la présente invention est de mettre à profit
EMI2.4
vis-à-via des lipides exogènen les propriété de'la carnitine qui furent ainsi démontrées à l'égard des lipide endogènes.
Lors de perfusions lipidiques effectuées chez des sujets ,.
EMI2.5
ayant aubi une intervention chirurgicale et nt trouvant soues narcose ou aner;thés3,a eétiéralet il a été constaté que le taux ¯\ d'acétone dans le Banc total pouvait n'élever jusqu'à 12 mg par 100 ml, alors que Banc perfusion lipidique d'autres on pont-opératoires étudié parallèlement présentaient, il raison,
EMI2.6
de leur état de jetne, un taux d'acétone sanguin moyen de. 6 n$" par 100 ml de sang total.
<Desc/Clms Page number 3>
EMI3.1
Pr contre, l'administration d'une émulsion lipidique . en ttaz-oci-ition avec la. carnitine chez po eajots ayaat eubi " - #; ¯ . une intervention chirurgicale a permis de eonotatar une tt<t- bilia6tion du pu et de lu rtcerve alcalin du 6'"&, ..
L'association d'oaulalon st de carnitinsra utilisée 1 cet effet oor1"f:It'ondlJit il la formule suivante Huile de graine do coton 15 g 1,Ccîthir-e (le Soja (rrctiol.l1(Íe) 1,2 g,*- - Dextrone 4 g Emulaifinnt polyoxyetliylênique 0t> g * 1... C)-I.l'itine 0t15 t" . , ±1;1.11 dintillée q.a. 100 JIll D",ulz'pl3 6muleios. t;ulJceptiblee de produire le szôsas effet peuvent comporter une t-ourco de lipides autroc que l'huile de graine de coton comme, par exemple, l'huile de Soja (exempt* de l'huile de aénamet l'huila de Carthatue* De la* la teneur en lipides peut varier entre 10 et 20X suivant l'apport 0;\10.1'1'11(0 auquel on .1"\lh,J t.e aboutir.
Les émulniotin utilisés peuvent atiniî Ittro ut.hbiliu6e.s par d'autres emulairiantit tels que lllciLlt1hc de JI1\1I.Q d'oeuf, polYflQrblttt't, ttlcoyleulfonate d'alcoolf gritu, gl.Yct5rldau J.nt.Ul't'8t<d'ifii:s sur support polyoxYflléth1lenique.
Au lieu do dextrose, on pout utiliser du corbitol ou de la glu- carine. On peut muni joindre des antioxydanta du type a-tocophérol ou tH;!1 ee;t<rn. En fin lu 1-carnitine peut etro remplacé pur 1. dl"Cttr<titine et le pourCt:nt!\t-;e do l'une ou l'autre de ces RubataR" ceu peut eti-e v;.rio attire 1 at 3â,da la quantité de lipides en-
EMI3.2
ployée.
EMI3.3
Citons A'titre tÎ' bXçc.l7.C
EMI3.4
t
EMI3.5
1) Huile de eu.411 (fx"Mpt (101 phouphtttidea) 10 g Lbcithino de jntre d'oeuf 0t6 % 30rbjtol 3 d.Curnitioe 0fl g Enu distillée qtn# 100 1111
<Desc/Clms Page number 4>
EMI4.1
2) Huile de eésaroe 20 g' .j Acide cétostéarylsulfonique 0,1 g, Glycérides .ntersstr.fiéa sur support 2 g polyoxyméthylénique '-?*'' "''# Glycérine j 2 a' ; '' < - .V 1-Carnitine .0,3 8' ", "¯:,,::,;;:, .- Eau distillée q.8. 100 1It1 .:',:
. "' 3) Huile de Carthame , .9 gaz Polyzorbate 80 ) 0,9 g .....'/.
Ac6tuto de DL-a-tocophérol 0,05 $ ' '# Dextrose a" ", . cI, b i. ".l' "'< 1-Carnitlne 0,2 g ' ;# ' t,.: , .
Eou dÜtilléè q.a. 100 zn,,w. '' Outre l'action propre . la carnitine sur le oëtabolierge den ucidee gras, on peut aussi mettre à profit son action, . .. sur lu résorption intestinale des lipides en 1 'associant d des t:l1ulniona lipidiques destinées à une administration orale' ou entcrnle. Loo 6mulaionn lipidiques utilisablee dans Ce but comportent les m3e8 cooHtitubJJLe que les émulaione lipidiques de.stin6f>/'1 à la perfubiole mais peuvent contenir une teneur plus ;. < importante en lipides (teneur pouvant aller jusqu'à 6%).
Il est bien entendu qu'aussi bien dans le cas des émulsion. lipidiques à usage purontéral que dans le cas des émulsions lipi" " diquea à usage enterai, il seratt possible d'employer la carni tine en administra Lion séparée de façon in produire dans 11orga.. n.t'tt.e mme, les effetn de l'association.
<Desc / Clms Page number 1>
EMI1.1
A $ .3 \ .: C! A T IvN D '; LA C ".1'1 1'1 '! NE HAS Lipidic Etalh: IGI4.
EMI1.2
The prii5ente invention does not relate to a ..aoo.A, .tior: t '; do the 41- or 1-carnitint, ci-npr '.- a dnocoet carrliU.t1.,. - '' "',,,' of mu18iou l1p1d & quen intended for the infusion or" # ', the oral t \ dmini fd.l'ta t10n or nt.fr "lt) this as4unistion having cocife goal to obtain a better utilil11 \ UÓn tissue lipids in the enti of dedqui, the inetabalic fiber and., especially in * 1 ': 1 Lt uyndr';) 1: I \ <J8 of undernutrition 'et101olh 4i ..'. verne, pre- and poat '-operatoireu, poat-infectîeux, little very * iU- MftHqmc, leu hypotropnles, the ebn of nenouciencit or leu cachexies (the burns, Lut ttuisionte lipi'tiquea!. have currently adIl1niatr ... dn8 citr, of malnutrition tela than those mentioned oi-dt * 8U in order to dtutuure z 1'organise a sufficient e * loric contribution aouj a reasonable volume.
<Desc / Clms Page number 2>
EMI2.1
We oomprwud, copondunt, tt this alest verified <xp4ri- rsrr: tslHr.ont, which the introduction of large quantities of Kraiaaett Anna l 'or gnn Lutta n'ttcoompt.gno de - /; # production of uutonic bodies and consequently by a 6tuk plus or Gloinu tiot d'fidoctoe.
With a view to fraai7 i tu the use of graîlla # 4 thus administered some nutoura have already pràcaniué the adBiHitt "simultaneous traction of a certain number of substances such as mt.hi.onitie, riboflHvino ascorbic acid) the attoidt IIicatimic uride # gaucarra, thiamine $ pyridoxide co-snxynia A # heparin and other heparoid substances.
Cnrnitin is known to have bio- properties.
EMI2.2
eliimiquen allowing to ftivorize the oxidation of acids 8; r <(t by the living cell. Neck constixtationa experimental ofCec -, - killed in vitro were confirmed in vivo and in particular in the
EMI2.3
lupine on an empty stomach where it is confirmed that the supplyine stabilizes the pH and the ulcality reserve of Dt, ng $, which indicates that the / substance, reduced ec.used, causes a better utilization of lipids by the orgun3.rzue. ¯ ,; The object of the present invention is to take advantage of
EMI2.4
vis-à-via exogenous lipids the properties of carnitine which were thus demonstrated with regard to endogenous lipids.
During lipid infusions carried out in subjects,.
EMI2.5
having undergone a surgical intervention and not finding its narcosis or aner; teas3, was etiéral and it was observed that the level ¯ \ of acetone in the total bench could not rise up to 12 mg per 100 ml, whereas bench infusion lipid of others on surgical bridge studied in parallel presented, he is right,
EMI2.6
of their state of jetne, an average blood acetone level of. $ 6 "per 100 ml of whole blood.
<Desc / Clms Page number 3>
EMI3.1
Pr against, the administration of a lipid emulsion. in ttaz-oci-ition with the. carnitine in po eajots ayaat eubi "- #; ¯. a surgical intervention resulted in the early development of pu and 6 '" & alkaline reserve.
The association of oaulalon and carnitinsra used 1 this effect oor1 "f: It'ondlJit the following formula Cottonseed oil 15 g 1, Ccîthir-e (Soya (rrctiol.l1 (Íe) 1.2 g , * - - Dextrone 4 g Polyoxyetliylene emulaifinnt 0t> g * 1 ... C) -I.itin 0t15 t "., ± 1; 1.11 dintillated qa 100 JIll D", ulz'pl3 6muleios. T; ulJceptiblee de produce the szôsas effect can include a t-ourco of autroc lipids than cottonseed oil such as, for example, soybean oil (free * from aenamet oil and Carthatue oil * From the * la lipid content can vary between 10 and 20X depending on the input 0; \ 10.1'1'11 (0 which we .1 "\ lh, J you end up.
The emulniotin used can be used in Ittro ut.hbiliu6e.s by other emulairiantit such as egg JI1 \ 1I.Q lllciLlt1hc, polYflQrblttt't, alcohol ttlcoyleulfonate, gl.Yct5rldau J.nt.Ul't ' 8t <of ifi: s on a polyoxYflléth1lenique support.
Instead of dextrose, corbitol or glucose can be used. Antioxidantants of the α-tocopherol or tH;! 1 ee; t <rn type can be attached. In the end read 1-carnitine can etro replaced pure 1. dl "Cttr <titin and the perCt: nt! \ T-; e do one or the other of these RubataR" ceu can eti-e v; .rio attracts 1 at 3â, in the amount of lipids in-
EMI3.2
bent.
EMI3.3
Let us quote A'title tî 'bXçc.l7.C
EMI3.4
t
EMI3.5
1) Oil of eu.411 (fx "Mpt (101 phouphtttidea) 10 g Lbcithino of egg jntre 0t6% 30rbjtol 3 d.Curnitioe 0fl g Enu distilled qtn # 100 1111
<Desc / Clms Page number 4>
EMI4.1
2) Esaroe oil 20 g '.j Cetostearylsulfonic acid 0.1 g, Glycerides .ntersstr.fiéa on a 2 g polyoxymethylene support' -? * '' "'' # Glycerin j 2 a ';' '<- .V 1 -Carnitine .0,3 8 '"," ¯: ,, ::, ;;:, .- Distilled water q.8. 100 1It1.:' ,:
. "'3) Safflower oil, .9 Polyzorbate 80 gas) 0.9 g .....' /.
Ac6tuto de DL-α-tocopherol 0.05 $ '' # Dextrose a "",. cI, b i. ".l '"' <1-Carnitlne 0.2 g '; #' t,.:,.
E or dÜtilléè q.a. 100 zn ,, w. '' Besides own action. carnitine on the oëtabolierge den ucidee gras, one can also take advantage of its action,. .. on intestinal absorption of lipids by combining it with lipid t: l1ulniona intended for oral or intcrnle administration. Loo 6 lipid emulations usable for this purpose include the cooHtitubJJLe m3e8 that lipid emulation of.stin6f> / '1 to the perfubiole but may contain a higher content ;. <high in lipids (content up to 6%).
It is understood that as well in the case of emulsions. lipid for puronteral use that in the case of lipid emulsions for enteral use, it would be possible to use the carni tine administered separately in such a way as to produce it in the organism. from the Association.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE639532A true BE639532A (en) |
Family
ID=203903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE639532D BE639532A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE639532A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
DE2921312A1 (en) * | 1978-05-25 | 1979-12-06 | Claudio Cavazza | PHARMACEUTICAL PRODUCT AND ITS USE IN A COMPLETELY PARENTERAL DIET |
DE3037479A1 (en) * | 1979-10-05 | 1981-05-21 | Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma | PHARMACEUTICAL COMPOSITION FOR PARENTERAL NUTRITION FROM L-CARNITIN OR ACYL-L-CARNITINES |
DE3026368A1 (en) * | 1980-07-11 | 1982-02-18 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | NUTRITIONAL SOLUTION FOR COMPLETE PARENTERAL NUTRITION AND FOR ENHANCED ENERGY PRODUCTION |
DE3339052A1 (en) * | 1982-10-29 | 1984-05-03 | Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma | PHARMACEUTICAL PREPARATION FOR IMPROVING THE BIOCHEMICAL AND BEHAVIOR PARAMETERS IN SENILITY |
EP0627161A1 (en) * | 1993-06-02 | 1994-12-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them |
-
0
- BE BE639532D patent/BE639532A/fr unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
DE2921312A1 (en) * | 1978-05-25 | 1979-12-06 | Claudio Cavazza | PHARMACEUTICAL PRODUCT AND ITS USE IN A COMPLETELY PARENTERAL DIET |
DE3037479A1 (en) * | 1979-10-05 | 1981-05-21 | Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma | PHARMACEUTICAL COMPOSITION FOR PARENTERAL NUTRITION FROM L-CARNITIN OR ACYL-L-CARNITINES |
DE3026368A1 (en) * | 1980-07-11 | 1982-02-18 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | NUTRITIONAL SOLUTION FOR COMPLETE PARENTERAL NUTRITION AND FOR ENHANCED ENERGY PRODUCTION |
DE3339052A1 (en) * | 1982-10-29 | 1984-05-03 | Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma | PHARMACEUTICAL PREPARATION FOR IMPROVING THE BIOCHEMICAL AND BEHAVIOR PARAMETERS IN SENILITY |
EP0627161A1 (en) * | 1993-06-02 | 1994-12-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0138931B1 (en) | Dermatological composition and preparation method thereof | |
US5714512A (en) | Compositions containing taxane derivatives | |
EP0522936A1 (en) | Taxane derivatives containing compositions | |
EP0424282B1 (en) | Sun tanning cosmetic preparation | |
FR2934954A1 (en) | FLUORESCENT EMULSION OF INDOCYANINE GREEN | |
EP0514665A1 (en) | Oil-soluble antioxidant mixture | |
FR2604906A1 (en) | EYE DROPS | |
FR2832065A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF | |
FR2934955A1 (en) | ENCAPSULATION OF LIPOPHILIC OR AMPHIPHILIC THERAPEUTIC AGENTS IN NANOEMULSIONS | |
BE639532A (en) | ||
FR2914188A1 (en) | Pharmaceutical composition, useful as medicine, preferably as drugs in the treatment of degenerative diseases, comprises oxime based chloestenone compounds or their esters or derivatives, and oil or its mixture | |
FR2609998A1 (en) | NOVEL ANTIOXIDANT SUBSTANCES DERIVED FROM AMINO ACIDS | |
CN103976901A (en) | Coenzyme Q10 and tea polyphenol loaded micro-nano carrier, as well as preparation and application methods thereof | |
FR2560523A1 (en) | OPHTHALMIC SOLUTION CONTAINING PRANOPROFEN AND BORIC ACID | |
EP0302769B1 (en) | Lipid emulsion for parenteral or enteral nutrition | |
EP0913147A1 (en) | System comprising a phosphonic acid derivative and a metabisulfit for stabilization of ascorbic acid | |
JP2006008720A (en) | Renal function-improving agent | |
FR2609394A1 (en) | AQUEOUS SOLUTION CONTAINING QUINOLONE CARBOXYLIC ACID | |
Cheikh et al. | Étude in vitro de l’effet antifalcémiant des globules rouges et de l’activité antioxydante d’extraits de la poudre de racines de Maytenus senegalensis Lam (Celestraceae) | |
EP0434628A1 (en) | Composition for cosmetics or pharmaceutical use | |
CN108853054A (en) | A kind of gambogicacid nano structured lipid carrier and preparation method thereof of cyclic peptide modification | |
Kiese et al. | The treatment of experimental cyanide poisoning by hemiglobin formation | |
WO1997024125A2 (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
EP0520865B1 (en) | Use of acid derivatives for the preparation of a pediculicidal medicament | |
CA2493074A1 (en) | Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |